Company Filing History:
1 out of 3 
1 out of 1 
1 out of 2 Years Active: 2022
Title: Paul Pentel: Innovator in Nicotine Addiction Treatment
Introduction
Paul Pentel is a notable inventor based in Minneapolis, MN (US). He has made significant contributions to the field of nicotine addiction treatment through his innovative research and development. His work focuses on creating solutions that aid in smoking cessation and address nicotine-related health issues.
Latest Patents
Pentel holds a patent for nicotine-binding antibodies. This patent describes novel nicotine-binding antibodies and methods for using them to treat nicotine addiction, facilitate smoking cessation, and address nicotine overdose or poisoning. His innovative approach has the potential to change the landscape of nicotine addiction treatment.
Career Highlights
Throughout his career, Paul Pentel has worked with various companies, including Antidote Therapeutics, Inc. and Blink Biomedical. His experience in these organizations has allowed him to develop and refine his ideas, contributing to advancements in medical treatments related to nicotine.
Collaborations
Pentel has collaborated with notable individuals in his field, including Matthew W. Kalnik and Thomas Thisted. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Paul Pentel's work in developing nicotine-binding antibodies showcases his commitment to addressing nicotine addiction and improving public health. His contributions to this field are invaluable and highlight the importance of innovation in medical research.